Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20111166 | 0.90 | HDAC1 (0.61) | HDAC1HDAC2HDAC3PKMHDAC6 | |
| SCHEMBL21696570 | 0.90 | MEN1 (0.57) | MEN1KMT2AHRH3PKM | |
| SCHEMBL30002109 | 0.86 | SLC6A5 (0.58) | HDAC1HDAC2HDAC3HRH3SLC6A5 | |
| SCHEMBL30002020 | 0.83 | ALDH1A1 (0.65) | MEN1KMT2AHDAC1HDAC2PKM | |
| SCHEMBL30001630 | 0.83 | MAOB (0.60) | HDAC1HDAC2HDAC3MMP1ADAM17 | |
| SCHEMBL30002303 | 0.80 | SLC6A5 (0.53) | KMT2ASLC6A5 | |
| SCHEMBL14287797 | 0.80 | HRH3 (0.58) | HRH3PTGER4SMN1; SMN2 | |
| SCHEMBL17136513 | 0.79 | MMP8 (0.53) | MEN1KMT2AHDAC1HDAC2HDAC3 | |
| SCHEMBL21696758 | 0.79 | FKBP1A (0.58) | MEN1KMT2APKMSMN1; SMN2 | |
| SCHEMBL21697246 | 0.79 | FKBP1A (0.58) | MEN1KMT2APKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205195-A1 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | AMTIXBIO CO., LTD. (KR) | 2025-06-26 | — | — | US | claimed |
| US-20250034083-A1 | METHODS FOR PREPARING BENZYLOXYBENZYLAMINE AMINO ACID DERIVATIVES | AMTIXBIO CO., LTD. (KR) | 2025-01-30 | — | — | US | claimed |
| US-20250034085-A1 | COMPOSITION AND METHODS FOR PREVENTING OR TREATING PHYTOPATHOGENIC FUNGAL INFECTION | AMTIXBIO CO., LTD. (KR) | 2025-01-30 | — | — | US | claimed |
| US-20250034084-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MYCOSIS | AMTIXBIO CO., LTD. (KR) | 2025-01-30 | — | — | US | claimed |
| EP-4349329-A1 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | Amtixbio Co., Ltd. (KR) | 2024-04-10 | — | — | EP | claimed |
| CN-117677382-A | Benzyloxy benzylamino amino acid derivatives that modulate TSLP/TSLPR signaling | 阿米蒂比奥有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-110325509-B | Functional derivative compounds of alanine and proline amino acids and pharmaceutical compositions containing the same | 阿米蒂比奥有限公司 | 2024-02-02 | — | — | CN | claimed |
| WO-2022255801-A1 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | (주)앰틱스바이오 | 2022-12-08 | — | — | WO | claimed |
| US-20250205195-A1 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | AMTIXBIO CO., LTD. (KR) | 2025-06-26 | — | — | US | disclosed |
| US-20250034083-A1 | METHODS FOR PREPARING BENZYLOXYBENZYLAMINE AMINO ACID DERIVATIVES | AMTIXBIO CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-20250034084-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MYCOSIS | AMTIXBIO CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-20250034085-A1 | COMPOSITION AND METHODS FOR PREVENTING OR TREATING PHYTOPATHOGENIC FUNGAL INFECTION | AMTIXBIO CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| US-20250034082-A1 | FUNCTIONAL DERIVATIVE COMPOUNDS OF ALANINE AND PROLINE AMINO ACIDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | AMTIXBIO CO., LTD. (KR) | 2025-01-30 | — | — | US | disclosed |
| EP-4349329-A1 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | Amtixbio Co., Ltd. (KR) | 2024-04-10 | — | — | EP | disclosed |
| CN-117677382-A | Benzyloxy benzylamino amino acid derivatives that modulate TSLP/TSLPR signaling | 阿米蒂比奥有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-110325509-B | Functional derivative compounds of alanine and proline amino acids and pharmaceutical compositions containing the same | 阿米蒂比奥有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-116836083-A | Functional derivative compounds of alanine and proline amino acids and pharmaceutical compositions containing the same | 阿米蒂比奥有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2022255801-A1 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | (주)앰틱스바이오 | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034083-A1 | METHODS FOR PREPARING BENZYLOXYBENZYLAMINE AMINO ACID DERIVATIVES | BCAT2, BCAT1, DAO | MEN1 2172/4885KMT2A 1657/4885HDAC1 3967/4885 |
| US-20250034082-A1 | FUNCTIONAL DERIVATIVE COMPOUNDS OF ALANINE AND PROLINE AMINO ACIDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | PEPD, BCAT1, ANPEP | MEN1 2657/4885KMT2A 3096/4885HDAC1 2889/4885 |
| US-20250034084-A1 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MYCOSIS | ERG28, BCAT2, AADAT | MEN1 1063/4885KMT2A 3000/4885HDAC1 3661/4885 |
| US-20250034085-A1 | COMPOSITION AND METHODS FOR PREVENTING OR TREATING PHYTOPATHOGENIC FUNGAL INFECTION | PEPD, PREP, ANPEP | MEN1 2795/4885KMT2A 3439/4885HDAC1 3497/4885 |
| US-20250205195-A1 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | TSLP, IL2RA, TRPC7 | MEN1 4612/4885KMT2A 3585/4885HDAC1 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.